SCHEMBL14778705

SCHEMBL14778705

CSc1nc2c(NCc3ccccc3)ncnc2[nH]1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 3/20 0.53
CSF1R P07333 2/20 0.53
CCNB2 O95067 2/20 0.53
CCNB1 P14635 2/20 0.53
CCNB3 Q8WWL7 2/20 0.53
EGFR P00533 5/20 0.52
LMNA P02545 3/20 0.48
CDK2 P24941 2/20 0.48
TSHR P16473 2/20 0.48
MAPK1 P28482 2/20 0.48
CYP1A2 P05177 1/20 0.48
CYP2D6 P10635 1/20 0.48
PI4KA P42356 2/20 0.46
PI4K2B Q8TCG2 2/20 0.46
PI4K2A Q9BTU6 2/20 0.46
PI4KB Q9UBF8 2/20 0.46
GALR3 O60755 2/20 0.46
NR2F2 P24468 2/20 0.46
RAB9A P51151 1/20 0.46
TMIGD3 P0DMS9 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14778707 0.83 CSF1R (0.69) CDK1CSF1RCCNB2CCNB1CCNB3
SCHEMBL31732167 0.81 CSF1R (0.70) CDK1CSF1RCCNB2CCNB1CCNB3
SCHEMBL14778602 0.81 CSF1R (0.54) CDK1CSF1RCCNB2CCNB1CCNB3
SCHEMBL14780386 0.80 CCNB2 (0.56) CDK1CCNB2CCNB1CCNB3LMNA
SCHEMBL14778796 0.80 CSF1R (0.53) CDK1CSF1RCCNB2CCNB1CCNB3
SCHEMBL14780085 0.80 EGFR (0.54) CDK1CSF1RCCNB2CCNB1CCNB3
SCHEMBL14779312 0.80 CSF1R (0.53) CDK1CSF1RCCNB2CCNB1CCNB3
SCHEMBL14780185 0.80 CSF1R (0.53) CDK1CSF1RCCNB2CCNB1CCNB3
SCHEMBL14779413 0.80 CSF1R (0.53) CDK1CSF1RCCNB2CCNB1CCNB3
SCHEMBL14779729 0.79 EGFR (0.52) CDK1CSF1RCCNB2CCNB1CCNB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2755977-B1 6,8-DISUBSTITUTED PURINE COMPOSITIONS AND THEIR PHARMACEUTICAL AND COSMETIC USE Univerzita Palackého v Olomouci (CZ) 2016-11-02 EP disclosed
EP-2755977-A1 6, 8- DISUBSTITUTED PURINE COMPOSITIONS AND THEIR PHARMACEUTICAL AND COSMETIC USE Univerzita Palackého v Olomouci (CZ) 2014-07-23 EP disclosed
WO-2013037333-A1 6, 8- DISUBSTITUTED PURINE COMPOSITIONS AND THEIR PHARMACEUTICAL AND COSMETIC USE UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2013-03-21 WO disclosed
US-20130072506-A1 6,8-DISUBSTITUTED PURINE COMPOSITIONS ZAHAJSKA LENKA (CZ) 2013-03-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072506-A1 6,8-DISUBSTITUTED PURINE COMPOSITIONS UNG, PNP, UMPS CDK1 624/4885CSF1R 2693/4885CCNB2 388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.